Janus Living, Inc. 8-K

What Happened

• Janus Living, Inc. announced the closing of a registered underwritten public offering of 48,300,000 shares of Class A‑1 common stock (includes full exercise of a 6,300,000 share overallotment). Related underwriting documents are dated March 19, 2026.
• Concurrently, the company and its operating subsidiary entered a Credit Agreement (closing date March 23, 2026) providing a $500 million revolving credit facility and a $100 million delayed‑draw term loan facility (with the option to expand total facilities up to $1.5 billion subject to lender commitments).
• Janus also executed key operating, management and governance documents with Healthpeak and its affiliates: an amended and restated operating agreement for Janus Living OP, LLC; a management agreement with Healthpeak Investment Management, LLC; an exclusivity agreement; a stockholders agreement giving Healthpeak director‑nomination rights; a registration rights agreement; and director indemnification agreements. The company filed amended Articles of Amendment and Restatement (Mar 17, 2026) and Amended and Restated Bylaws (effective Mar 19, 2026).

Key Details

• Offering: 48,300,000 Class A‑1 shares issued, including 6.3M overallotment shares; Class A‑1 par value $0.01.
• Management Agreement: $10.0 million annual base management fee (subject to adjustments tied to gross book value changes), initial three‑year term with renewals; manager to be reimbursed for documented third‑party expenses.
• Credit Facilities: $500M revolver (matures Mar 22, 2030, two 6‑month extension options) and $100M DDTL (term loans mature Mar 21, 2031); pricing based on SOFR + leverage/rating‑based margins; financial covenants include max leverage ratio ≤ 0.60x, max secured debt ratio ≤ 0.40x, min fixed charge coverage ≥ 1.50x and min unsecured interest coverage ≥ 1.75x.
• Healthpeak rights: registration/demand rights covering 214,734,026 Class A‑1 shares (including 75,917,780 shares issuable on redemption of common units); board nomination rights equal to 40% of the board if Healthpeak owns ≥30% of outstanding common stock, or one nominee if it owns ≥5% but <30%.

Why It Matters

• Capital & liquidity: The public offering plus new $600M of committed credit capacity (with potential to increase) materially bolster Janus Living’s liquidity to support operations, acquisitions or debt refinancing.
• Governance and control: The management agreement and stockholders agreement significantly increase Healthpeak’s operational role and governance influence (board nomination rights and broad registration/demand rights), which could affect strategic decisions and future equity transactions.
• Financial constraints: The credit facilities include standard covenants that limit leverage and require minimum coverage ratios; those covenants can restrict how aggressively the company finances growth or uses secured borrowing.
• Investor considerations: Retail investors should note potential dilution from the offering, the sizable registration/demand rights that allow Healthpeak to sell or force offerings of shares, and that management of day‑to‑day operations will be performed by Healthpeak’s manager under a multi‑year fee arrangement.

(For full legal terms, covenants and exhibits, see the filed exhibits referenced in the 8‑K.)